ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
4,982.77
-1.57%
US Tech 100
16,391.60
-3.28%
다우존스 지수
37,645.59
-0.84%
Bitcoin
75,479.00
-1.05%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. AMEX

  6. OS Therapies Incorporated (OSTX) 시세

OS Therapies Incorporated

OS Therapies Incorporated (OSTX)

AMEX
1.31
-0.12
(-8.39%)
마감 09 4월 5:00AM
15분 지연
1.29
-0.02
(-1.53%)
시간외 거래: 8:59AM
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
1.29
매수가
-
매도가
-
거래량
148,959
1.26 일간 변동폭 1.50
1.29 52주 범위 7.00
market_cap
27.946M
전일 종가
1.43
개장가
1.50
최근 거래 시간
500
@
1.29
(formt)
마지막 거래 시간
재정 규모
US$ 199,297
VWAP
1.3379
평균 볼륨(3m)
1,258,438
발행 주식
21,663,811
배당수익률
-
주가수익률
0.00
주당순이익(EPS)
-
매출
-
순이익
-6.38M

OS Therapies Incorporated 정보

OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adult... OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. At OST, we are trying to answer the calls for new treatments, considering there have been no new treatments for OS in over 30 years. OST has expanded the pipeline beyond Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including Breast, Esophageal and Lung cancer. With the addition of OST-tADC, considered a next generation Antibody Drug Conjugate (ADC) platform technology, we will be targeting Ovarian, Lung and Pancreatic cancer. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.ostherapies.com
본부
Middletown, Delaware, USA
설립됨
-
OS Therapies Incorporated is listed in the Pharmaceutical Preparations sector of the 아메리카 증권거래소 with ticker OSTX. The last closing price for OS Therapies was US$1.43. Over the last year, OS Therapies shares have traded in a share price range of US$ 1.29 to US$ 7.00.

OS Therapies currently has 21,663,811 shares in issue. The market capitalisation of OS Therapies is US$30.98 million.

OSTX 최신 뉴스

추가 뉴스

Form 8-K - Current report
Edgar (US Regulatory)
01 4월 2025
OSTX (-8.39%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
01 4월 2025
OSTX (-8.39%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
01 3월 2025
OSTX (-8.39%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.16-11.03448275861.451.79991.291790481.46769762CS
4-0.33-20.37037037041.621.79991.291140481.55760158CS
12-3.37-72.31759656654.6671.2912584382.77841691CS
26-1.96-60.30769230773.2571.296137742.82439689CS
52-2.71-67.75471.295028772.93473824CS
156-2.71-67.75471.295028772.93473824CS
260-2.71-67.75471.295028772.93473824CS

OSTX - Frequently Asked Questions (FAQ)

What is the current OS Therapies share price?
The current share price of OS Therapies is US$ 1.29
How many OS Therapies shares are in issue?
OS Therapies has 21,663,811 shares in issue
What is the market cap of OS Therapies?
The market capitalisation of OS Therapies is USD 30.98M
What is the 1 year trading range for OS Therapies share price?
OS Therapies has traded in the range of US$ 1.29 to US$ 7.00 during the past year
What is the reporting currency for OS Therapies?
OS Therapies reports financial results in USD
What is the latest annual profit for OS Therapies?
The latest annual profit of OS Therapies is USD -6.38M
What is the registered address of OS Therapies?
The registered address for OS Therapies is 18 MANASSAS DRIVE, MIDDLETOWN, DELAWARE, 197093802
What is the OS Therapies website address?
The website address for OS Therapies is www.ostherapies.com
Which industry sector does OS Therapies operate in?
OS Therapies operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
UVIX2x Long VIX Futures ETF
US$ 92.13
(25.36%)
8.59M
FOXOFOXO Technologies Inc
US$ 0.1387
(23.18%)
122.98M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
US$ 18.54
(22.38%)
29.47M
UVXYProShares Ultra VIX Short Term Futures ETF
US$ 47.8495
(20.38%)
33.07M
GPUSHyperscale Data Inc
US$ 2.60
(19.27%)
116.18k
LGPSLogProstyle Inc
US$ 3.6979
(-28.20%)
408.93k
IBOImpact Biomedical Inc
US$ 0.6481
(-25.36%)
3.06M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 3.55
(-21.81%)
112.41M
CLDICalidi Biotherapeutics Inc
US$ 0.4034
(-18.69%)
680.28k
MITQMoving iMage Technologies Inc
US$ 0.5512
(-17.42%)
254.27k
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 8.25
(-9.84%)
488.74M
SPYSPDR S&P 500
US$ 496.48
(-1.57%)
162.84M
FOXOFOXO Technologies Inc
US$ 0.1387
(23.18%)
122.98M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 9.85
(5.01%)
121.56M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 3.55
(-21.81%)
112.41M

OSTX Discussion

게시물 보기
swingingRichard swingingRichard 1 월 전
OSTX being promoted by some pr firm called RedChip on Bloomberg. 
👍️0
tw0122 tw0122 2 월 전
$1.92 ..The Company recently completed a $7.1 millionfinancing in January 2025 and has sufficient capital into mid 2026..
(2) sell the Priority Review Voucher (PRV) it would receive from the FDA BLA approval prior to the September 30, 2026 PRV deadline to a larger pharmaceutical company at prevailing market prices (most recent PRV sale transaction was $150 million), (3) commercialize OST-HER2 in osteosarcoma and (4) then expand the clinical development of OST-HER2 into breast cancer and other larger solid tumor indications for additional revenue potential.
👍️0
JPetroInc JPetroInc 2 월 전
too much debt AND the CBO is a lying POS shyster who destroys SH value



C-Suites my royal right butt cheek ...!

just look at what Gerald Commissiong did to AMBS and TOMDF

drove both into insolvency and stole everything he could via serial dilution from his SH's

its just that plain and simple...!



Gerald Commissiong - WAPOS
👍️0
tw0122 tw0122 2 월 전
Yes only played premarket to much debt here 
👍️0
Monksdream Monksdream 2 월 전
OSTX under $3
👍️0
JPetroInc JPetroInc 2 월 전
don't touch it...

unless you're Jack be nimble Jack be quick...

AJMHO
👍️0
tedpeele tedpeele 2 월 전
I'm seeing 1.6m float
👍️0
glenn1919 glenn1919 2 월 전
OSTX...................................................newone.....................................https://stockcharts.com/h-sc/ui?s=ostxp=W&yr=1&mn=3&dy=0&id=p96837884856
👍️0
tw0122 tw0122 2 월 전
$4.10 + 104% went to $5s last run January but profit taking hitting bigger now 
👍️0
JPetroInc JPetroInc 2 월 전
I wouldn't touch ANYTHING Gerald Commissiong is involved with...

did you see the last P&D they pulled in Dec., 24

AJMHO
👍️0
tw0122 tw0122 2 월 전
$3.36 + 70% Guess will find out later flip out time ..
 The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
👍️0
JPetroInc JPetroInc 2 월 전
interesting - wonder where they'll get their funding

and if it will be toxic - Gerald...?
👍️0
tw0122 tw0122 2 월 전
OSTK 3.06 + 52% 
👍️0
tw0122 tw0122 2 월 전
OSTX $2.30 + 15% .. NEW YORK--(BUSINESS WIRE)--Feb. 14, 2025--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the commercial manufacture of OST-HER2. 
👍️0
tw0122 tw0122 3 월 전
Didn't trade it but see you under $4 maybe lol thanks
👍️0
TheFinalCD TheFinalCD 3 월 전
$OSTX in yesterday's filing pic.twitter.com/2l25LO7e3J— brentkhack (@brentkhack_TX) January 15, 2025
👍️0
tw0122 tw0122 3 월 전
Lung action $8s + 92% 17m floater 
👍️0
JPetroInc JPetroInc 6 월 전
looking good Gerald...!

IMHO, you'll have this trading at $0.00028 in record time



here comes the Astoria Queens financial mafia wrecking crew to help assist you in your next financial debacle

so much for running TOMDF into insolvency and jumping ship to this firm which didn't last long:

Fortitude Advisors LLC

https://fortitudeadvisors.com/team/

"He is also the Chief Business Officer at OS Therapies, Inc. starting in 2024 and the Managing Partner at Fortitude Advisors LLC since 2019."

https://uk.marketscreener.com/insider/GERALD-COMMISSIONG-A19LFK/

I give Gerald Commissiong 6 months before OSTX fire's his arse - and for good measure...!

MOO pathetic
👍️0
JPetroInc JPetroInc 6 월 전
uh ho - Gerald Commissiong OSTX's new Chief Business Officer executive named...

and is the same old same old serial dilution 'scam artist' from AMBS & TOMDF

here we go again folks...!



buyers be ware - check these other 2 tickers for the catastrophic results by this Stanford Univ. Financial Engineering hack

https://ostherapies.com/leadership/

SMH - can't make this stuff up - sad but true...!

MOO tool
👍️0

최근 히스토리

AMEX
OSTX
OS Therapies
COIN
BKSSUSD
BlockShares
LSE
BD98
Orbita.23.1.30
LSE
TI40
Orbta 22-1.29 A
LSE
BE15
Orbita.23.1.30
BOV
MSRO3
MAESTRO LOCADORA ON
AQSE
DXIBX.GB
Deutsche Bank Luxembourg
LSE
FERG
Ferguson Enterprises
LSE
FLRK
Frk Korea Etf
LSE
3SMD
Amd 3xs $
DGFX
ACCEUSDT
Accel Chain
NASDAQI
OMXI10CAPEUR
OMX Iceland 10 Cap EUR
LSE
70VX
Paragon 12 C1bs
LSE
32DH
Trafford A3
LSE
60IP
Westpac Per.frn
LSE
PH56
Shawbrook 99
Delayed Upgrade Clock
ADVFN Logo
대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지